Literature DB >> 26264925

Quinoxalines Potential to Target Pathologies.

María Tristán-Manzano, Antonio Guirado, María Martínez-Esparza, Jesús Gálvez, Pilar García-Peñarrubia, Antonio J Ruiz-Alcaraz1.   

Abstract

The study of quinoxalines has increased immeasurably during the last two decades, due firstly to their relatively simple chemical synthesis, which has generated a vast variety of compounds with diverse structural modifications, and secondly, to the wide therapeutic potential and biological activities exhibited by this family of compounds. Quinoxalines constitute a rising biomedical class of low-molecular weight heterocyclic compounds with potential functions as antitumour, anti-inflammatory, antibacterial, antiviral, antifungal, antiparasitic and antidiabetic agents, as well as being of interest for the potential treatment of glaucoma, insomnia, cardiovascular and neurological diseases, among others. However, a deeper knowledge of the molecular targets of quinoxalines that fulfil a key role in certain pathologies is required for the development of new and more specific drugs through a rational design strategy to avoid undesirable side effects. In the present review, we summarize the most important molecular targets of the quinoxaline derivatives discovered to date, thus providing a first reference index for researchers to identify the potential targets of their quinoxalines derived collections, which could facilitate the development of new quinoxaline- based therapies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26264925     DOI: 10.2174/0929867322666150812144104

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  4 in total

1.  Anti-leukemia activity of 4-amino-2-aryl-6,9-dichlorobenzo[g]pteridines.

Authors:  Antonio J Ruiz-Alcaraz; Violeta Carmona-Martínez; Antonio Guirado; Jesús Gálvez; María Martínez-Esparza; Pilar García-Peñarrubia
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-11-21       Impact factor: 3.000

2.  Expression of LAIR-1 (CD305) on Human Blood Monocytes as a Marker of Hepatic Cirrhosis Progression.

Authors:  María Martínez-Esparza; Antonio José Ruiz-Alcaraz; Violeta Carmona-Martínez; María Dolores Fernández-Fernández; Gonzalo Antón; María Muñoz-Tornero; Miriam Lencina; Inmaculada Pagán; Jesús de la Peña; Pilar García-Peñarrubia
Journal:  J Immunol Res       Date:  2019-03-24       Impact factor: 4.818

3.  Spectral Probe for Electron Transfer and Addition Reactions of Azide Radicals with Substituted Quinoxalin-2-Ones in Aqueous Solutions.

Authors:  Konrad Skotnicki; Slawomir Ostrowski; Jan Cz Dobrowolski; Julio R De la Fuente; Alvaro Cañete; Krzysztof Bobrowski
Journal:  Int J Mol Sci       Date:  2021-01-10       Impact factor: 5.923

4.  New quinoxaline compounds as DPP-4 inhibitors and hypoglycemics: design, synthesis, computational and bio-distribution studies.

Authors:  Yasmin M Syam; Manal M Anwar; Somaia S Abd El-Karim; Samia A Elseginy; Basma M Essa; Tamer M Sakr
Journal:  RSC Adv       Date:  2021-11-17       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.